A competitor bites the dust, GEN-003 to be shelved by Genocea (seems they will try to sell it, but the recent results weren't too promising). With our vaccine giving similar results it will be interesting if we follow suit or if we see if we continue to push on in the hope of re-jigging to get better outcomes from a further phase II study.
More:
https://www.acsh.org/news/2017/09/25/bombs-away-genoceas-herpes-vaccine-goes-down-flames-11874
"For those of you who may have been counting on Genocea's GEN-003 to cure or treat your genital herpes, this is a very bad day. The company just announced that it was discontinuing the development of 003 as a potential vaccine for herpes simplex virus (HSV) and was "exploring strategic alternatives. ""
A competitor bites the dust, GEN-003 to be shelved by Genocea...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.94 |
Change
0.180(1.53%) |
Mkt cap ! $252.4M | |||
| Open | High | Low | Value | Volume |
| $11.98 | $12.00 | $11.51 | $31.55K | 2.657K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 33 | $11.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.94 | 171 | 2 |
View Market Depth
| Last trade - 10.29am 08/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |